A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain

Inclusion Criteria: * Filipino patients with moderate to severe non-cancer pain with an onset of 12 weeks or less from the baseline visit Patient is experiencing either an acute exacerbation of non-cancer pain or pain that has progressed to the point with the duration of at least 7 days and in the prescribing physician's judgment requires treatment with a Schedule II opioid * Medically stable on the basis of routine physical examination, medical history, and vital signs at the time of baseline visit Exclusion Criteria: * Refuse to protocol-defined use of effective contraception * Pregnant and lactating women * Patients with severe renal and hepatic impairment, and having or suspected paralytic ileus * Patients with conditions where drugs with mu-opioid receptor agonist activity are contraindicated * Patients with acute intoxication with alcohol, hypnotics, centrally acting analgesics, or psychotropic drugs or receiving other mu-opioid receptor agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, and sedatives * Patients who are receiving Monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days * Patients with documented history of increased intracranial pressure, impaired consciousness, coma and seizure